studies

melanoma (ML), ipilimumab alone vs. pembrolizumab alone, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.59 [1.19; 2.11] KEYNOTE-006 (3 week), 2015 (REV) 1.45 [1.10; 1.91] 1.51[1.24; 1.84]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,112moderatenot evaluable deaths (OS) (extension)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.47 [1.15; 1.88] KEYNOTE-006 (3 week), 2015 (REV) 1.47 [1.15; 1.87] 1.47[1.24; 1.75]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,112moderatenot evaluable PFS (extension)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.64 [1.34; 2.01] KEYNOTE-006 (3 week), 2015 (REV) 1.64 [1.34; 2.01] 1.64[1.42; 1.89]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,112moderatenot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.72 [1.38; 2.16] KEYNOTE-006 (3 week), 2015 (REV) 1.72 [1.39; 2.13] 1.72[1.48; 2.01]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,112moderatenot evaluable objective responses (ORR)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 0.27 [0.17; 0.41] KEYNOTE-006 (3 week), 2015 (REV) 0.28 [0.18; 0.43] 0.27[0.20; 0.37]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,112moderatenot evaluable STRAE (any grade)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.49 [0.92; 2.42] KEYNOTE-006 (3 week), 2015 (REV) 1.59 [0.97; 2.60] 1.54[1.09; 2.17]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable STRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74] 1.08[0.07; 17.38]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable TRAE (any grade)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 0.62 [0.41; 0.93] KEYNOTE-006 (3 week), 2015 (REV) 0.86 [0.58; 1.28] 0.73[0.53; 1.02]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)225%1,067moderatenot evaluable TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.19 [0.77; 1.85] KEYNOTE-006 (3 week), 2015 (REV) 1.22 [0.78; 1.90] 1.21[0.88; 1.65]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 0.54 [0.02; 16.23] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74] 0.73[0.06; 9.52]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable TRAE leading to discontinuation (any grade)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.35 [0.71; 2.53] KEYNOTE-006 (3 week), 2015 (REV) 0.81 [0.46; 1.44] 1.03[0.63; 1.68]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)225%1,067moderatenot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74] 1.08[0.07; 17.38]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Abdominal pain TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74] 1.08[0.07; 17.38]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Alopecia TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74] 1.08[0.07; 17.38]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 0.54 [0.05; 6.00] KEYNOTE-006 (3 week), 2015 (REV) 2.17 [0.07; 64.92] 0.86[0.12; 6.13]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Arthralgia TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74] 1.08[0.07; 17.38]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Asthenia TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 2.18 [0.20; 24.20] KEYNOTE-006 (3 week), 2015 (REV) 4.35 [0.20; 97.02] 2.83[0.42; 18.94]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Chills TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74] 1.08[0.07; 17.38]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Colitis TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 5.18 [1.73; 15.52] KEYNOTE-006 (3 week), 2015 (REV) 2.92 [1.20; 7.11] 3.66[1.84; 7.32]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Constipation TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74] 1.08[0.07; 17.38]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Cough TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74] 1.08[0.07; 17.38]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74] 1.08[0.07; 17.38]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Diabetes TRAE (grade 3-4)detailed resultsKEYNOTE-006 (3 week), 2015 (REV) 0.54 [0.02; 16.17] 0.54[0.02; 16.17]KEYNOTE-006 (3 week), 2015 (REV)10%533NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.38; 3.15] KEYNOTE-006 (3 week), 2015 (REV) 2.57 [0.66; 10.04] 1.50[0.65; 3.48]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Dry skin TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74] 1.08[0.07; 17.38]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Dyspnoea TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 2.18 [0.07; 65.16] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.07; 17.40] 1.43[0.17; 12.30]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 3.28 [0.34; 31.78] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.22; 5.41] 1.57[0.42; 5.83]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Headache TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74] 1.08[0.07; 17.38]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Hepatitis TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 0.36 [0.04; 3.48] KEYNOTE-006 (3 week), 2015 (REV) 0.21 [0.02; 1.84] 0.27[0.06; 1.30]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 2.18 [0.07; 65.16] KEYNOTE-006 (3 week), 2015 (REV) 2.17 [0.07; 64.92] 2.17[0.20; 24.03]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 4.37 [0.20; 97.37] KEYNOTE-006 (3 week), 2015 (REV) 2.17 [0.20; 24.11] 2.82[0.42; 18.92]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 0.54 [0.02; 16.23] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74] 0.73[0.06; 9.52]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Increase AST TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 4.37 [0.20; 97.37] KEYNOTE-006 (3 week), 2015 (REV) 2.17 [0.20; 24.11] 2.82[0.42; 18.92]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Increased ALT TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 4.37 [0.20; 97.37] KEYNOTE-006 (3 week), 2015 (REV) 2.17 [0.20; 24.11] 2.82[0.42; 18.92]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 2.18 [0.07; 65.16] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.07; 17.40] 1.43[0.17; 12.30]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Myalgia TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.07; 17.46] KEYNOTE-006 (3 week), 2015 (REV) 2.17 [0.07; 64.92] 1.43[0.17; 12.31]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Myositis TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74] 1.08[0.07; 17.38]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74] 1.08[0.07; 17.38]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Nephritis TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 2.18 [0.07; 65.16] KEYNOTE-006 (3 week), 2015 (REV) 2.17 [0.07; 64.92] 2.17[0.20; 24.03]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74] 1.08[0.07; 17.38]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Paraesthesia TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 2.18 [0.07; 65.16] KEYNOTE-006 (3 week), 2015 (REV) 2.17 [0.07; 64.92] 2.17[0.20; 24.03]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 2.18 [0.07; 65.16] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.07; 17.40] 1.43[0.17; 12.30]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Pruritic rash TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74] 1.08[0.07; 17.38]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Pruritus TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74] 1.08[0.07; 17.38]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Pyrexia TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74] 1.08[0.07; 17.38]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Rash TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74] 1.08[0.07; 17.38]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Uveitis TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 1.09 [0.02; 54.94] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74] 1.08[0.07; 17.38]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Vomiting TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 0.54 [0.02; 16.23] KEYNOTE-006 (3 week), 2015 (REV) 1.08 [0.02; 54.74] 0.73[0.06; 9.52]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable Weight decreased TRAE (grade 3-4)detailed resultsKEYNOTE-006 (2 week), 2015 (REV) 2.18 [0.07; 65.16] KEYNOTE-006 (3 week), 2015 (REV) 2.17 [0.07; 64.92] 2.17[0.20; 24.03]KEYNOTE-006 (2 week), 2015 (REV), KEYNOTE-006 (3 week), 2015 (REV)20%1,067moderatenot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-06-22 21:19 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 2,283,284,70,235,285,68,127,128,286,69,129 - treatments: 329,558

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons